Latest news with #CamileFarah
The Age
3 days ago
- Business
- The Age
Optiscan unveils high-tech imaging device for veterinarians
Optiscan Imaging has unveiled its high-tech microscopic imaging device InSpecta, designed for use by veterinary clinics to boost diagnostics and treatment options for the huge animal healthcare market, including the lucrative pet segment. The new-age imaging device provides a first step for the company into the veterinary medicine market and expands its product suite to a growing key industry. The company's InSpecta device is designed to deliver real-time, non-invasive imaging to improve diagnostic and treatment outcomes for companion animals, including dogs, cats and horses. With a whopping 76 million dogs and 60 million cats estimated in the United States alone, the existing demand for veterinary services is significant. The demand for treating complex conditions, such as cancer, is expected to grow the industry further and may deliver lucrative opportunities if the technology can pass muster. 'We are thrilled to reveal the InSpecta device to both investors and veterinary medicine professionals.' Optiscan chief executive officer and managing director Camile Farah Optiscan has partnered with the University of Minnesota's College of Veterinary Medicine to conduct testwork on the device and use the data to help support the required regulatory submissions. The veterinary device market may provide a faster pathway to approval than the human medical device industry, where the company is also working, potentially opening the door to earlier revenue options. The company will demonstrate the device at the prestigious American College of Veterinary Internal Medicine conference in Kentucky next week. Optiscan chief executive officer and managing director Camile Farah said: 'We are thrilled to reveal the InSpecta device to both investors and veterinary medicine professionals. Our design team should be extremely proud of their efforts to get this market-changing device to the reveal stage. InSpecta is based on the company's life sciences imaging platform, ViewnVivo, and offers veterinarians an easy-to-use, portable and robust imaging device, which is purposefully designed for their particular needs.' Farah said the device can be used in both in-vivo and ex-vivo applications, such as imaging tissue pathology samples. The company incorporated feedback from vets during its design stage.
Sydney Morning Herald
3 days ago
- Business
- Sydney Morning Herald
Optiscan unveils high-tech imaging device for veterinarians
Optiscan Imaging has unveiled its high-tech microscopic imaging device InSpecta, designed for use by veterinary clinics to boost diagnostics and treatment options for the huge animal healthcare market, including the lucrative pet segment. The new-age imaging device provides a first step for the company into the veterinary medicine market and expands its product suite to a growing key industry. The company's InSpecta device is designed to deliver real-time, non-invasive imaging to improve diagnostic and treatment outcomes for companion animals, including dogs, cats and horses. With a whopping 76 million dogs and 60 million cats estimated in the United States alone, the existing demand for veterinary services is significant. The demand for treating complex conditions, such as cancer, is expected to grow the industry further and may deliver lucrative opportunities if the technology can pass muster. 'We are thrilled to reveal the InSpecta device to both investors and veterinary medicine professionals.' Optiscan chief executive officer and managing director Camile Farah Optiscan has partnered with the University of Minnesota's College of Veterinary Medicine to conduct testwork on the device and use the data to help support the required regulatory submissions. The veterinary device market may provide a faster pathway to approval than the human medical device industry, where the company is also working, potentially opening the door to earlier revenue options. The company will demonstrate the device at the prestigious American College of Veterinary Internal Medicine conference in Kentucky next week. Optiscan chief executive officer and managing director Camile Farah said: 'We are thrilled to reveal the InSpecta device to both investors and veterinary medicine professionals. Our design team should be extremely proud of their efforts to get this market-changing device to the reveal stage. InSpecta is based on the company's life sciences imaging platform, ViewnVivo, and offers veterinarians an easy-to-use, portable and robust imaging device, which is purposefully designed for their particular needs.' Farah said the device can be used in both in-vivo and ex-vivo applications, such as imaging tissue pathology samples. The company incorporated feedback from vets during its design stage.
Sydney Morning Herald
27-05-2025
- Business
- Sydney Morning Herald
Optiscan software breakthrough will bring pathologists to the bedside
ASX-listed medical technology innovator Optiscan Imaging has just fired a major shot across the bow of the global diagnostics industry with the launch of its game-changing cloud-based telepathology platform prototype. The company confirmed it has reached the minimum viable product (MVP) stage for its secure streaming software, developed in collaboration with Canadian software firm Prolucid Technologies. Successful beta-testing of the new software means pathologists could soon dial in from anywhere in the world to stream live, high-resolution tissue scans captured by clinicians in real time via a secure cloud connection - whether a hospital theatre, remote clinic or a clinician in the deep Outback. In addition to viewing images, pathologists will be able to flag key areas, annotate pictures, generate reports and collaborate with surgeons or imaging specialists live or on demand. 'This platform is a potential game changer for global digital pathology.' Optiscan Imaging chief executive officer and managing director Dr Camile Farah The platform is designed to integrate seamlessly with Optiscan's range of digital imaging devices, including the company's InVue, InForm and InVivage systems. Optiscan Imaging chief executive officer and managing director Dr Camile Farah said: 'This platform is a potential game changer for global digital pathology, with particular relevance to regional, rural and remote healthcare settings where access to pathology expertise is limited. Our telepathology solution essentially brings the pathologist into the heart of the operating theatre and bridges the gap between surgery and pathology.' Optiscan says security is top of mind. All communications are encrypted, with personal patient data hidden or made anonymous. Only registered devices with valid digital certificates can access the system, which uses a WebRTC-based protocol to keep the upload lag time under half a second. The system has been designed as a Software as a Medical Device (SaMD), meaning it's ready to slot into everyday clinical use. It will let doctors stream images directly to each other, review scans later, share second opinions and generate reports - all while keeping patient data safe and secure.
The Age
27-05-2025
- Business
- The Age
Optiscan software breakthrough will bring pathologists to the bedside
ASX-listed medical technology innovator Optiscan Imaging has just fired a major shot across the bow of the global diagnostics industry with the launch of its game-changing cloud-based telepathology platform prototype. The company confirmed it has reached the minimum viable product (MVP) stage for its secure streaming software, developed in collaboration with Canadian software firm Prolucid Technologies. Successful beta-testing of the new software means pathologists could soon dial in from anywhere in the world to stream live, high-resolution tissue scans captured by clinicians in real time via a secure cloud connection - whether a hospital theatre, remote clinic or a clinician in the deep Outback. In addition to viewing images, pathologists will be able to flag key areas, annotate pictures, generate reports and collaborate with surgeons or imaging specialists live or on demand. 'This platform is a potential game changer for global digital pathology.' Optiscan Imaging chief executive officer and managing director Dr Camile Farah The platform is designed to integrate seamlessly with Optiscan's range of digital imaging devices, including the company's InVue, InForm and InVivage systems. Optiscan Imaging chief executive officer and managing director Dr Camile Farah said: 'This platform is a potential game changer for global digital pathology, with particular relevance to regional, rural and remote healthcare settings where access to pathology expertise is limited. Our telepathology solution essentially brings the pathologist into the heart of the operating theatre and bridges the gap between surgery and pathology.' Optiscan says security is top of mind. All communications are encrypted, with personal patient data hidden or made anonymous. Only registered devices with valid digital certificates can access the system, which uses a WebRTC-based protocol to keep the upload lag time under half a second. The system has been designed as a Software as a Medical Device (SaMD), meaning it's ready to slot into everyday clinical use. It will let doctors stream images directly to each other, review scans later, share second opinions and generate reports - all while keeping patient data safe and secure.
The Age
13-05-2025
- Business
- The Age
Optiscan, Mayo make headway blending robotics with imaging
Optiscan and US-based Mayo Clinic have made significant headway down a mutual path as they look to blend digital laser technology with new-age robotic surgery, with a vision to complete their joint project within the next 12 months. The two firms have combined project teams to collaborate on an imaging system aimed at giving medical practitioners enhanced real-time imaging during surgery and allow for the immediate precision treatment of patients. Experts from the two companies have been tasked with developing Optiscan's digital confocal laser-technology in the form of a robot-compatible endomicroscopic imaging system, primarily focused on breast cancer surgeries. Both groups have focussed on developing the relevant accessories to allow for Optiscan's imaging probe to be incorporated into the robotic surgical world. The next phase of the project is expected to take place at Mayo Clinic's Florida campus. With greater accuracy on tissue classification, cancer cell determination and cancer margin assessment, the new technology is expected to streamline the surgical process, improve decision-making and reduce the potential for follow-up surgeries. 'We are thrilled with the outcomes delivered to date from our collaboration with the Mayo Clinic.' Optiscan Imaging chief executive officer and managing director Dr Camile Farah The plan remains on track to develop a new style of imaging system within a two-year period, after a 'Know-How' agreement was signed by the duo 12 months ago. All targeted milestones set for the first 12 months have been achieved. The agreement focuses on the mutual assignment and ownership of intellectual property (IP) rights between the parties involved, ensuring the clarity and protection of respective IP assets. Several of the milestones achieved include the definition of system requirements, concept development and feasibility assessment, a review of system requirements, design inputs and enhancements, along with prototyping and benchtop testing.
